

# State of SITC | 2018

## Membership Business Meeting

November 10, 2018 | Walter E. Washington Convention Center

**Lisa H. Butterfield, PhD**

President



Society for Immunotherapy of Cancer

# Agenda

- Call to Order
- Introductions
- State of SITC
  - Election Results
  - 2017 Financial Reports
  - 2018 Membership Reports (to Date)
  - 2018 Society Accomplishments
- *Forward Fund*
- New Fellowships
- A Look to the Future
- Thank You to Volunteers
- Supporter Recognition



# Introductions



Society for Immunotherapy of Cancer

# 2018 Board of Directors

## Officer Directors:

### **President (2016-18)**

*Lisa H. Butterfield, PhD*

### **Vice President (2016-18)**

*Mario Sznol, MD*

### **Secretary/Treasurer (2018-20)**

*Kim A. Margolin, MD*

### **Immediate Past President (2016-18)**

*Howard L. Kaufman, MD, FACS*

## At-Large Directors:

*Charles G. Drake, MD, PhD (2016-19)*

*Leisha A. Emens, MD, PhD (2016-19)*

*Jérôme Galon, PhD (2015-18)*

*Kristen Hege, MD (2016-19)*

*David Kaufman, MD, PhD (2018-20)*

*Samir N. Khleif, MD (2015-18)*

*Pamela S. Ohashi, PhD (2015-18)*

## Ex-Officio Directors:

*Pedro J. Romero, MD - Editor-in-Chief, JITC*

*James Gulley, MD, PhD, FACP – NCI Liaison*

*Marc Theoret, MD – FDA Liaison*



# State of SITC



Society for Immunotherapy of Cancer

# 2018 Election Results:

## Vice President Elect (2019-20)



**Patrick Hwu, MD**

*University of Texas*

*MD Anderson Cancer Center*



Society for Immunotherapy of Cancer

# 2018 Election Results: At-Large Board of Directors (2019-21)



**Ana Carrizosa Anderson, PhD**  
*Harvard Medical School*



**Daniel S. Chen, MD, PhD**  
*IGM Biosciences, Inc.*



**Marcela V. Maus, MD, PhD**  
*Massachusetts  
General Hospital*



Society for Immunotherapy of Cancer


# 2017 Financial Report




Society for Immunotherapy of Cancer




# Total Unrestricted Net Assets (Since 2000)



# 2017 Unrestricted Income



# 2017 Total Expenses




# Membership




Society for Immunotherapy of Cancer

# Membership Totals (Since 2011)



# Membership by Category-2018



# 2018 Society Accomplishments



Society for Immunotherapy of Cancer

# SOCIETY FOR IMMUNOTHERAPY OF CANCER 2016 – 2018 STRATEGIC PRIORITIES



## OUR **VISION**

SITC aims to make cancer immunotherapy a standard of care and the word "cure" a reality for cancer patients everywhere

## OUR **VALUES**

- Innovation
- Integration
- Interaction
- Leadership
- Translation

SITC  
MEMBERS

OUR  
GOALS

COLLABORATION

EDUCATION  
& SCIENTIFIC  
EXCHANGE

ENGAGEMENT

SCIENCE &  
RESEARCH

GLOBAL  
IMPACT

## CULTIVATE MEANINGFUL **RELATIONSHIPS**

SITC recognizes the importance of collaborations in the fight to "cure" cancer and aims to foster meaningful partnerships with those who have similar goals. SITC will make dedicated efforts to increase interaction with government agencies, parallel and peripheral organizations, networks and expanded target demographics from around the globe to make the goal of a cure for cancer a reality

## SERVE AS THE LEADING **RESOURCE**

Through enhancing our live and online educational program offerings, setting industry standards and using our Journal to disseminate relevant and timely information, SITC aspires to provide the best education, scientific exchange and networking opportunities in order to enrich the cancer immunotherapy field

## CREATE A **NETWORK** OF STAKEHOLDERS

Broadening SITC-based initiatives will attract new volunteers, members and organizational collaborations that can be utilized to poise SITC as the leader in the field world-wide. Meaningful engagement with stakeholders will allow SITC to be a main hub of information and provide opportunities for interaction amongst key leaders in the field who are working tirelessly to make the word "cure" a reality for cancer patients

## ADVANCE THE SCIENCE **GLOBALLY**

The field of cancer immunotherapy spans the globe and so do our members. In an effort to better serve all of our members and partners, SITC aims to establish a new international advisory committee, utilize global partnerships, bridge geographical distances through technology and develop targeted education that accounts for regional and international considerations, all in an effort to advance the science and application of cancer immunotherapy world-wide

## SEEK THE BEST **RESEARCH**

In an ever-evolving field, it is important to challenge the status quo and seek out innovative research that can drive the field into the future. To further explore and develop tumor immunology and cancer immunotherapy, SITC will dare to challenge the current thinking and propel immunotherapy forward. With a focus on research, SITC will use the Journal to engage in hot topics, creating cancer immunotherapy guidelines, engage in lobbying and advocacy efforts, and charter a forward-thinking committee dedicated to innovation in key areas of interest



# Collaboration



Society for Immunotherapy of Cancer

# Cultivated Meaningful Relationships

- **ASCO-SITC Clinical Immuno-Oncology Symposium**
  - Over **1,000** attendees
- **SITC Cancer Immunotherapy ConnectED Online Collaborations**
  - Partnering to provide users content from **5** major patient advocacy organizations including Cancer Support Community
- **Collaborative Education Programs (CEP)**
  - **20** programs covering **6** countries (USA, Italy, France, Germany, Spain and Egypt)



# Cultivated Meaningful Relationships

## ▪ SITC Partnerships

- **Hematology Oncology Pharmacist Association (HOPA)** – ACI Programs
- **NCI** – Education and Training Landscape Analysis
- **Association for Molecular Pathology** – Guidance and Standards for Tumor Mutational Burden
- **Bonnie J. Addario Lung Cancer Foundation** – Patient Reported Outcomes Project
- **FDA** – Immune-modified Response Criteria in Cancer Immunotherapy Clinical Trials Workshop
- **FNIH Biomarkers Cancer Consortium** – Dr. Butterfield on the Steering Committee; Drs. McNeel & Gulley serving as SITC representatives for their project: *Prostate Cancer Study of Active Surveillance in Low Grade Prostate Cancer*



# Cultivated Meaningful Relationships

- **Stand Up To Cancer** - Supported 5 young investigators to join Convergence Teams
  - **Project 1: Using Artificial Intelligence to Predict Molecular Pathways and Clinical Outcomes**  
Team Leader: Ernest Fraenkel, PhD, Massachusetts Institute of Technology
  - **Project 2: Single Cell Functional Multi-omics to characterize and Monitor CAR T Therapy**  
Team Leader: Rong Fan, PhD, Yale University
  - **Project 3: Connecting Immune Health and Tumor Biology in Gynecologic Cancers**  
Team Leader: John Wherry, PhD, University of Pennsylvania
  - **Project 4: Correlating Immunological Health to Cancer Susceptibility**  
Team Leader: Mark Davis, PhD, Stanford University
  - **Project 5: Computational Deconstruction of Neoantigen-TCR Degeneracy for Cancer Immunotherapy**  
Team Leader: Benjamin Greenbaum, PhD, at the Icahn School of Medicine at Mount Sinai



# Engagement



Society for Immunotherapy of Cancer

# Increased Opportunities for Engagement

- **SITC Committees and Task Forces**
  - 22 Committees, 18 Subcommittees, and 2 Task Forces
- **Professional Interest Communities (PIC)**
  - Early Career Focus
  - 5 communities to date
- **Dedicated Volunteer Portal**
  - Members create a volunteer portal
  - SITC staff and leaders can post opportunities for easy matching
  - 600+ volunteers



# Increased Opportunities for Engagement

- **Women in Cancer Immunotherapy Network (WIN) Established**

- Reception during SITC 2017 and 2018
- Increased women in SITC Leadership roles

- **In the numbers:**

- Board of Directors
  - 36% female, 2 of the 3 newly elected At-Large Directors for 2019 are female
- Committee membership has 27% female participation
- Annual Meeting faculty is 32% female
- Abstract Authors are 40% female



# Education & Scientific Exchange



Society for Immunotherapy of Cancer



# Served as the Leading Resource for Information and Education

- **SITC Cancer Immunotherapy CONNECT**

- More than **1 million** page views in 2018
- More than **2,000** resources available to visitors



- **SITC Cancer Immunotherapy ConnectED**

- More than **75** FREE online classes
- Contains more than **14 years** of enduring materials



# Served as the Leading Resource for Information and Education

- **Annual Meeting & Pre-Conference Programs (SITC 2018)**
  - More than 4,859 attendees
  - 795 abstracts submitted (25% increase over 2017)
- **2018 Interim Workshops**
  - Cancer Immune Responsiveness Workshop  
(manuscript is being finalized for submission)
  - Immuno-Oncology Biomarkers  
(manuscript submitted and awaiting peer review)



# Served as the Leading Resource for Information and Education

- **Advances in Cancer Immunotherapy™ (ACI)**

- 14 live programs
- Quarterly webinars

- **SITC Cancer Immunotherapy Guidelines**

- 2018: Published 2 manuscripts
  - *Cutaneous Melanoma (update)*
  - *Non-Small Cell Lung Cancer*
- New CIG webinars



# Global Exchange

- **SITC Membership**
  - **2,400** members, including over **800** new members
  - Increased geographic coverage with members from **42** countries
- **Global audience for ConnectED**
- **Publication of Global Immunoscore Validation Project**
  - Pagès, Franck et. Al. (2018). *International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study*. The Lancet. 391.
  - United medical centers from around the world
- **SITC representation at international CEPs**
  - SITC financially sponsored **6** speakers and recommended **27**



# Science & Research



Society for Immunotherapy of Cancer

# Sought the Best Research

- **SITC Sparkathon: Early Career Scientists addressing obstacles in the field**
  - **Sparkathon Class of 2017**
    - **29** young investigators
    - Updates presented at SITC 2018
  - **Sparkathon Class of 2018**
    - **28** young investigators
    - Findings to be presented at SITC 2019



# Sought the Best Research

- ***Journal for the ImmunoTherapy of Cancer (JITC)***

- Received **8.374** Impact Factor
- Top **8%**
- More than **200%** increase in submissions



- **White Papers**

- Published **3** SITC white papers in 2018

- **Immunoscore Validation Project**

- Published in May 2018
- Included more than **3,500** patients in **13** countries



# Policy & Advocacy



Society for Immunotherapy of Cancer



# Key Issues SITC Influenced in 2018

## ■ Science & Research

- Areas of Focus in 2018
  - Clinical trial design
  - Endpoints
  - Toxicity management
  - Biomarkers
- Congressional Report Language to NHI/NCI
  - Basic research and training in I-O
  - Additional fellowships for mid-career I-O researchers
- Engagement with NCI (education/training efforts)



# Key Issues SITC Influenced in 2018

## ■ Regulatory

- Meetings with congressional staffers
  - Advocating for cancer patients
  - Educating policy makers
- Congressional report language to FDA
  - Standardize toxicity reporting in clinical trials
- Engagement with FDA (OCE clinical rounds and workshops)



# Key Issues SITC Influenced in 2018

- **Quality/Value**

- Comments to CMS on CAR T reimbursement and Medicare IPPS rule FY19
- Feedback to new House Healthcare Innovation Caucus on value-based payment reform



# *Forward Fund*



Society for Immunotherapy of Cancer

# The *Forward* Fund has provided more than \$2.2 million in fellowship awards since 2014

- **33 Abstract Travel Awards in 2018**
- **2018 SITC Fellowship Awards**
  - SITC-Bristol-Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship Award (\$200,000; two years) to: **David Liu, MPH, MS** – *Dana-Farber Cancer Institute*
  - SITC-AstraZeneca Postdoctoral Cancer Immunotherapy in Combination Therapies Clinical Fellowship Award (\$100,000; one year) to:  
**Bryan D. Choi, MD, PhD** – *Massachusetts General Hospital & Harvard Medical School*
  - SITC-Merck Cancer Immunotherapy Clinical Fellowship Award (\$100,000; one year) to:  
**Kelly G. Paulson, MD, PhD** – *Fred Hutchinson Cancer Research Center*
- **SITC-Stand Up to Cancer “Convergence 2.0” Fellowships**



# New Fellowships to Launch in 2019

- **SITC-AstraZeneca Immunotherapy in Lung Cancer (Early Stage NSCLC) Clinical Fellowship Award**
  - One-Year Award
  - **\$100,000** in support
  - Submission opens January 2019
- **SITC's Holbrook Kohrt, MD, PhD Cancer Immunotherapy Translational Memorial Fellowship Award** (Sponsored by Genentech)
  - Holbrook Edwin Kidd Kohrt, MD, PhD (1977–2016)
  - One-Year Award
  - **\$100,000** in support
  - Submission opens January 2019



# New Fellowships to Launch in 2019

## ▪ 2019 NCI Immunotherapy Fellowship

- Co-sponsored by the NCI Center for Cancer Research and SITC and made possible, in part, by an educational grant from EMD-Serono
- This is a one-year program at the CCR in Bethesda, MD
- Provides a young investigator with an opportunity to further their education and experience in the field of cancer immunotherapy
- Submission opens on November 14, 2018!



# A Look to the Future



Society for Immunotherapy of Cancer



# Key Initiatives for 2019

## Growing the Profession

- **Expand development and dissemination of Cancer Immunotherapy Guidelines**
  - To publish: *Acute Leukemia, Lymphoma and Head & Neck*
  - To update: *Renal Cell, Bladder (both in early stages of development)*
  - In development: *Multiple Myeloma and irAE*
  - Webinars to follow each publication
  - Dedicated mobile app to support the series
- **Collaborative Education Programs**
- **Meet-the-Expert Series**
- **Women in Cancer Immunotherapy Leadership Retreat**
- **Professional Interest Communities (PIC)**
- **Certification**



# Key Initiatives for 2019

## Advancing the Science

- **2019 Interim Workshops**

- Adoptive Cellular Therapies
- Tumor Immune Co-Evolution

- **White Papers from 2018 Workshops**

- Standardization of multispectral imaging techniques
- Comprehensive view on cancer immune responsiveness



# Key Initiatives for 2019

## Advancing the Science

### ■ Pathology Task Force

- New 21-member task force led by Carlo Bifulco, MD and Janis Taube, MD, MSC
- Two manuscripts are planned:
  - Theoretical paper proposing standards for multispectral imaging based on the experience and expertise of the Task Force
  - Data-backed paper wherein the minimum criteria for appropriate validation of multispectral imaging technologies will be tested
- Task Force members include at least one representative from each of the four NIH-funded Cancer Immune Monitoring & Analysis Center (CIMAC) labs, with whom we will be working closely in developing the second manuscript



# Key Initiatives for 2019

## Advancing the Science

**Biomarkers Committee:** The 68-member committee, led by Lisa H. Butterfield, PhD and Mary L. Disis, MD, FACP, was reorganized this year into the following subcommittees:

- **Resources and Useful Tools Subcommittee**

- Led by Holden T. Maecker, PhD and Siwen Hu-Lieskovan, MD, PhD
- Planning to update an existing technology primer, *“SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools – a compass in the land of biomarker discovery”*



# Key Initiatives for 2019

## Advancing the Science

### ■ Biomarkers Data Sharing Subcommittee

- Led by Alessandra Cesano, MD, PhD and Sergio Rutella, MD, PhD, FRCPath
- Planning to update a white paper previously published by the Biomarkers Task Force in 2016  
*“Novel technologies and emerging biomarkers for personalized cancer immunotherapy”*

### ■ Microbiome Subcommittee

- Led by Jennifer A. Wargo, MD, MMSc and Laurence Zitvogel, MD, PhD
- The microbiome is the focus of a half-day workshop at this year’s Annual Meeting focusing on harmonizing microbiome analyses in immunotherapy
- The information and discussions of this whole-day emersion will be used to help generate a manuscript to be published in 2019



# Key Initiatives for 2019

## Advancing the Science

### ■ Tumor Mutational Burden Subcommittee

- Led by Jianda Yuan, MD, PhD and Priti S. Hegde, PhD
- Development of a manuscript is in the early stages of planning, potentially in collaboration with the FoCR.

### ■ Cancer Immune Responsiveness Task Force

- 75-member task force
- Led by Francesco M. Marincola, MD and Alessandra Cesano, MD, PhD
- A manuscript will be submitted yet this year, based in part on discussions had during the CIR workshop's breakout sessions, focused on identifying key questions and strategizing how to move forward in five areas pertaining to immune responsiveness.



# Key Initiatives for 2019

## Policy & Advocacy

- **Quality Expert Panel**

- **New I-O measure concepts**

A group of experts will gather in February 14, 2019 to re-examine and re-evaluate existing oncology measures to address any gaps and lack of immunotherapy measures.

- **Build a survivor community**

- **I-O survivors to generate a unified voice!**

Their experience will offer invaluable perspective in the development of SITC generated patient materials and better articulate the value of I-O.



# Scientific Priorities (2019 - 2021)



Society for Immunotherapy of Cancer



# Scientific Priorities (2019-2021)

- **Strategic Planning Retreat**
  - **Review of Scientific Hurdles**
  - **Landscape Analysis**
  - **Identification of Top 5 Scientific Priorities**
  - **Reframing as NCI Provocative Questions**
- **Board of Directors Selection of Top Two with High Need/High Feasibility**
  - **Global Access and Impact**
  - **IO Toxicities**
  - **Big Data / Data Science**
  - **Biopsies and Biospecimens Collection**
  - **Immunoscore**





# A Special Thanks...



Society for Immunotherapy of Cancer

# Outgoing Board Members



**Jérôme Galon, MD**  
*Universite Pierre Et Marie Curie  
Sorbonne Universites*



**Samir N. Khleif, MD**  
*Georgetown University  
Medical Center*



**Pamela S. Ohashi, PhD**  
*Princess Margaret  
Cancer Centre*



Society for Immunotherapy of Cancer

# Volunteers

- Over the last year, over **600** volunteers have helped SITC to advance the field.
- As the **ONLY** member-driven society within the field of cancer immunotherapy, everything that you see and experience at SITC meetings, educational events and in publications is created through the remarkable leadership of our volunteers.



# 2018 Program Supporters (All Programs)

**7 Hills Pharma, LLC**

**AbbVie**

**Amgen**

**Astellas and Seattle Genetics**

**AstraZeneca Pharmaceuticals LP\***

**Bavarian Nordic A/S**

**Bayer Healthcare Pharmaceuticals**

**Bristol-Myers Squibb**

**\*Diamond Donor**

**Celgene Corporation**

**CytomX**

**Eli Lilly**

**Fluidigm**

**Genentech**

**Gilead Sciences**

**HalioDx**



Society for Immunotherapy of Cancer

# 2018 Program Supporters (All Programs)

**Incyte Corporation**

**Janssen Research & Development, LLC**

**Lilly Oncology**

**Mallinckrodt Pharmaceuticals**

**Merck & Co., Inc.**

**NanoString Technologies**

**Novartis Oncology**

**Novartis Pharmaceuticals Corporation**

**Parker Institute for Cancer Immunotherapy**

**Pfizer, Inc.**

**Pfizer/Merck KGaA**

**Prometheus Laboratories Inc.**

**Regeneron**

**Replimune**

**TESARO, Inc.**

